Browse by Phase
Phase 1 Clinical Trials
Phase 1 trials test a new drug or treatment in a small group (20–80 people) for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects.
Total Trials
584
Recruiting Now
584
Top Conditions in Phase 1
Frequently Asked Questions — Phase 1 Trials
What is tested in a Phase 1 clinical trial?
Phase 1 trials test a new drug or treatment in a small group of 20–80 people for the first time. The primary goals are to evaluate safety, determine a safe dosage range, identify side effects, and study how the drug is metabolized and excreted. Phase 1 trials typically enroll patients with the target condition who have exhausted standard treatment options, or healthy volunteers in some cases.
How long do Phase 1 clinical trials last?
Phase 1 trials typically last several months to one year depending on the drug, dose-escalation protocol, and follow-up period. The relatively small patient cohort and focused safety objectives make Phase 1 the shortest stage in clinical development. Some are extended into Phase 1/2 combined designs to simultaneously gather early efficacy signals.
Are Phase 1 clinical trials safe to join?
Phase 1 trials are the first human tests of a new intervention and carry the most uncertainty about safety. All Phase 1 studies must be approved by an Institutional Review Board (IRB) and operate under strict FDA oversight. Participants receive intensive monitoring throughout the study. While risks exist, Phase 1 protocols use conservative dosing and frequent safety assessments to protect participants.
Active Phase 1 Studies
NCT07527923 Phase 1
Recruiting
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult...
Condition
Healthy Volunteer
Enrollment
160 pts
Location
United States, Belgium
Sponsor
Regeneron Pharmaceuticals
NCT07102576 Phase 1
Recruiting
MDMA-Assisted Therapy for Mental Healthcare Providers
Condition
Mental Wellbeing
Enrollment
30 pts
Location
United States
Sponsor
Rachel Yehuda
NCT06952010 Phase 1
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants Wit...
Condition
Solid Tumor
Enrollment
303 pts
Location
United States
Sponsor
Exelixis
NCT07016152 Phase 1
Recruiting
An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogeni...
Condition
Klebsiella Pneumoniae Infection
Enrollment
40 pts
Location
Taiwan
Sponsor
Cho Pharma Inc.
NCT07260591 Phase 1
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
6 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT07675590 Phase 1
Recruiting
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administ...
Condition
Health Adult Subjects
Enrollment
18 pts
Location
United States
Sponsor
TIXiMED, Inc.
NCT05570422 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
Condition
Cervical Cancer
Enrollment
70 pts
Location
India, Thailand, United Kingdom
Sponsor
Kortuc, Inc.
NCT07524322 Phase 1
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Condition
Breast Cancer
Enrollment
63 pts
Location
United States
Sponsor
Regor Pharmaceuticals Inc.
NCT06313437 Phase 1
Recruiting
Revumenib in Combination With 7+3 + Midostaurin in AML
Condition
Acute Myeloid Leukemia
Enrollment
22 pts
Location
United States
Sponsor
Richard Stone, MD
NCT06721299 Phase 1
Recruiting
Clenbuterol to Target DUX4 in FSHD
Condition
Muscular Dystrophy, Facioscapulohumeral
Enrollment
30 pts
Location
United States
Sponsor
Jeffrey Statland
NCT07619339 Phase 1
Recruiting
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Condition
Non-Small Cell Lung Cancer
Enrollment
16 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT07257419 Phase 1
Recruiting
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted ...
Condition
Relapsed Pediatric ALL
Enrollment
70 pts
Location
United States
Sponsor
St. Jude Children's Research H
NCT06884098 Phase 1
Recruiting
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD...
Condition
Primary Hypercholesterolaemia
Enrollment
60 pts
Location
South Korea
Sponsor
Addpharma Inc.
NCT06922539 Phase 1
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung ...
Condition
Small Cell Lung Cancer
Enrollment
44 pts
Location
United States
Sponsor
SciTech Development, Inc.
NCT04678401 Phase 1
Recruiting
IS-free Treg HaploHCT
Condition
Stem Cell Transplant Complications
Enrollment
30 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT07136922 Phase 1
Recruiting
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid ...
Condition
Luteal Phase Insuffiency
Enrollment
20 pts
Location
United Kingdom
Sponsor
Calla Lily Clinical Care Ltd
NCT07444619 Phase 1
Recruiting
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Niv...
Condition
Soft Tissue Sarcomas
Enrollment
18 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04772456 Phase 1
Recruiting
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Condition
Glioma
Enrollment
5 pts
Location
United States
Sponsor
University of Maryland, Baltim
NCT02966665 Phase 1
Recruiting
: Vascular Function in Health and Disease
Condition
Chronic Obstructive Pulmonary Disease
Enrollment
420 pts
Location
United States
Sponsor
D. Walter Wray
NCT03999229 Phase 1
Recruiting
S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
Condition
Transfusion Related Complication
Enrollment
35 pts
Location
United States
Sponsor
James Reynolds
NCT05927571 Phase 1
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination...
Condition
Relapsed or Refractory Multiple Myeloma
Enrollment
120 pts
Location
Australia, Israel, South Korea
Sponsor
Genentech, Inc.
NCT06734871 Phase 1
Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/re...
Condition
B-Cell Non-Hodgkin Lymphoma
Enrollment
24 pts
Location
China
Sponsor
Aibin Liang，MD，Ph.D.
NCT07016971 Phase 1
Recruiting
CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
Condition
Chemotherapy-Induced Peripheral Neuropathy
Enrollment
12 pts
Location
United States
Sponsor
Milton S. Hershey Medical Cent
NCT05302037 Phase 1
Recruiting
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELI...
Condition
Cancer
Enrollment
12 pts
Location
Singapore
Sponsor
CytoMed Therapeutics Pte Ltd
NCT06553339 Phase 1
Recruiting
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Condition
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Enrollment
60 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology